J&J Medical Connect
milvexian

This information is intended for US patients and caregivers to access current scientific information about J&J Innovative Medicine products. It is prepared by Medical Information and is not intended to promote the use of our products, nor to provide medical advice.

milvexian
Patient Medical Information

Clinical Trial Participation - LIBREXIA

Last Updated: 11/18/2026

SUMMARY

  • Thank you for your inquiry regarding participating in a clinical trial to evaluate milvexian, an investigational factor XIa inhibitor being studied for prevention and treatment of major thrombotic conditions. Volunteers are critical partners in clinical research.
  • The LIBREXIA-STROKE and LIBREXIA-AF clinical trials remain active but are no longer accepting participants.
  • The LIBREXIA-ACS clinical trial has been discontinued.
  • To learn more about the milvexian LIBREXIA clinical trial program, please visit https://clinicaltrials.gov/ and use the following search terms: Milvexian, BMS-986177, JNJ-70033093.

BRISTOL MYERS SQUIBB AND JOHNSON & JOHNSON COLLABORATION

Milvexian is an oral investigational factor XIa inhibitor being studied for the prevention of major thrombotic conditions in a worldwide collaboration program between Bristol Myers Squibb and Johnson & Johnson. Milvexian is not currently approved for any use.

To read more about how Johnson & Johnson processes personal data, please visit https://innovativemedicine.jnj.com, select your country or region (in the upper right corner), and then click on Privacy Policy.

To read more about how Bristol Myers Squibb processes personal data, please visit https://www.bms.com, select your country (in the upper right corner), and then click on Privacy Policy.

Would you like to clear and leave your conversation? Message history will be lost.